Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
about
Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic ratsTezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different modelsDistinct ETA receptor binding mode of macitentan as determined by site directed mutagenesisComparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.Phosphodiesterase-5 activity exerts a coronary vasoconstrictor influence in awake swine that is mediated in part via an increase in endothelin production.Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes.The effect of tezosentan, a non-selective endothelin receptor antagonist, on shear stress-induced changes in arterial diameter of the anaesthetized dog.Blockade of endothelinergic receptors prevents development of proliferative vitreoretinopathy in mice.Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile.Estimation of endothelin-mediated vasoconstriction in acute pulmonary thromboembolism.Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups.
P2860
Q24685743-2399DCCE-54B1-4D6D-BFC8-3B9C4B33EB36Q34286576-8D298462-95A6-4CF4-A784-86E8017D71A0Q35256194-9BACF142-5803-4F6F-972C-67FDB4202D45Q35827520-3D3AA31B-DEC8-413F-A32E-614B29B8FF9AQ36510011-CA7AA994-B647-4540-B456-6FC6624F2F9FQ37211372-2C370305-3C9A-4B99-BF98-D346F5885B2AQ37629227-37B2EA89-C15F-4F16-A7E9-F8731C0888CBQ38426618-0859139A-3346-439D-838D-84E221EF3961Q39124034-9F161274-CBEF-4B3F-A32C-C04ADAE0B34DQ41821660-1B7B7451-E1C7-424C-B5A3-9F7CF7AAE2E7Q41907845-915249E4-828C-4CB8-A6E0-90E40601CCB4Q42145277-72BEB976-B1D3-4813-A6FD-42451D4D84D0Q42780477-37E452B3-A7E3-4027-8F79-F75AE9CC4EDAQ42829416-9511C40D-2DF5-4D1D-9E4C-95E34C888217Q46368139-474C6B5D-9C25-4056-873E-344D99B89FE1
P2860
Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Pharmacology of tezosentan, ne ...... t designed for parenteral use.
@en
Pharmacology of tezosentan, ne ...... t designed for parenteral use.
@nl
type
label
Pharmacology of tezosentan, ne ...... t designed for parenteral use.
@en
Pharmacology of tezosentan, ne ...... t designed for parenteral use.
@nl
prefLabel
Pharmacology of tezosentan, ne ...... t designed for parenteral use.
@en
Pharmacology of tezosentan, ne ...... t designed for parenteral use.
@nl
P2093
P1476
Pharmacology of tezosentan, ne ...... st designed for parenteral use
@en
P2093
Coassolo P
Löffler BM
P304
P407
P577
1999-08-01T00:00:00Z